 |
BioXCell presents the new InVivoMAb anti-mouse IL-27 p28 for in-vivo applications of checkpoint inhibitors
The MM27.7B1 monoclonal antibody reacts with the p28 subunit of mouse IL-27, a member of the IL-6/IL-12 cytokine family. IL-27 is a heterodimeric cytokine composed the EBI3 (Epstein-Barr virus induced gene 3) protein and the p28 subunit, also known as IL-30. Myeloid cells including macrophages, inflammatory monocytes, microglia, and dendritic cells are the dominant cellular sources of IL-27. These cells secrete IL-27 in response to TLR ligands and inflammatory cytokines. IL-27 p28 signals through IL-27 receptors (IL-27R) which are highly expressed by NK cells and activated T cells and to a lesser extent on B cells, naïve T cells, and others. IL-27 signaling has been shown to have both pro-inflammatory and anti-inflammatory effects. Signaling through IL-27R promotes Th1 polarization and IFN? production but also suppresses the differentiation and proliferation of Th2 and Th17 cells and induces the expression of IL-10. The MM27.7B1 clone has been shown to neutralize the bioactivity of IL-27 in vivo and in vitro.
DBA-ITALIA Srl
Via Umbria 10
20090 Segrate (Milano)
Tel. +39 02-26922300
Fax +39 02-26926058
Fax +39 02-26923535